^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Stimuvax (tecemotide)

    i
    Associations
    News

    Trials

    Company:
    EMD Serono, Ono Pharma, Pfizer
    Drug class:
    Immunostimulant, MUC1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Tecemotide (L-BLP25) in Prostate Cancer (EMR 63325-015) (NCT01496131)
    Phase 2
    EMD Serono
    Completed
    Last update posted :
    03/09/2018
    Initiation :
    10/24/2011
    Primary completion :
    11/25/2016
    Completion :
    11/25/2016
    MUC1
    |
    cyclophosphamide • goserelin acetate • Stimuvax (tecemotide) • cyclophosphamide intravenous
    L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases (NCT01462513)
    Phase 2
    Prof. Dr. Carl Schimanski
    Completed
    Last update posted :
    02/13/2018
    Initiation :
    08/01/2011
    Primary completion :
    12/31/2017
    Completion :
    01/31/2018
    MUC1
    |
    Stimuvax (tecemotide)
    Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer (FINGERPRINT) (NCT01731587)
    Phase 1
    Merck KGaA, Darmstadt, Germany
    Withdrawn
    Last update posted :
    02/28/2017
    Initiation :
    01/01/2001
    TGFB1 • IFNA1 • CRP
    |
    cyclophosphamide • Stimuvax (tecemotide) • cyclophosphamide intravenous
    Tecemotide (L-BLP25) in Rectal Cancer (SPRINT) (NCT01507103)
    Phase 2
    Merck KGaA, Darmstadt, Germany
    Completed
    Last update posted :
    01/13/2017
    Initiation :
    02/01/2012
    Primary completion :
    06/01/2014
    Completion :
    06/01/2014
    MSI • CD8 • IFNG • MLH1 • MSH6 • MUC1 • MSH2 • CEACAM5 • ISG20
    |
    MSI-H/dMMR
    |
    capecitabine • cyclophosphamide • Stimuvax (tecemotide) • cyclophosphamide intravenous
    Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy (NCT01094548)
    Phase 2
    Merck KGaA, Darmstadt, Germany
    Completed
    Last update posted :
    02/22/2016
    Initiation :
    01/01/2008
    Primary completion :
    02/01/2011
    Completion :
    03/01/2012
    IFNG • MUC1
    |
    MUC1 expression
    |
    cyclophosphamide • Stimuvax (tecemotide) • cyclophosphamide intravenous